I believe the excerpt below taken from the peer review is another very key statement as they say Brilacidin ALONE could handle everything needed to stop CV19.
----------------------------------------------------------------
Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control both viralload and the corresponding inflammatory damage due to SARS-CoV-2 [72], and mitigate bacterial coinfections. With its HDP mimetic properties—antivi-ral, immuno/anti-inflammatory, and antibacterial—brilacidin may be able to address the different disease parameters of COVID-19 within the one therapeutic treatment. The re-sults of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in ad-dition to standard of care, are highly anticipated.
Market Data 
Markets 
AI
